Shots:
- J&J has reported data from the P-III (Vivacity-MG3) trial assessing Imaavy + SoC (n=77) vs PBO + SoC (n=76) in gMG pts (N=199; 153 were Ab +ve), plus from an ongoing OLE trial. Also, enrolment is ongoing in the EPIC trial of Imaavy against efgartigimod
- The 24wk. Post-hoc analysis data showed adults receiving Imaavy + SoC were ~4x more likely to achieve sustained MSE (MG-ADL 0/1 for ≥8wks.), with these pts experiencing the greatest improvements in QoL vs those without sustained or no MSE
- In the OLE (96wks.), Imaavy showed sustained MG-ADL (-6.47) & QMG (-5.97) improvements, with 50% achieving MSE & ~32% sustained MSE for ≥8wks. OLE also showed >64% reduction in total IgG levels, with 57% reducing corticosteroids to ≤10 or ≤5 mg/day
Ref: J&J | Image: J&J | Press Release
Related News: Johnson & Johnson Gains EC Approval for Akeega to Treat Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
